interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Elagolix Sodium

Generic competition · all medicines · read 12 November 2026

Is there a generic of Elagolix Sodium, and who makes it?

Elagolix Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Elagolix Sodium1 dosage-form group in the Orange Book
0generic makers listed
  1. Elagolix Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Orilissa. No generic is listed as marketed.

20152020202520302035204001brand 2018data datePatent 7419983 listed to expire 6 July 2029Patent 11707464 listed to expire 14 March 2034Patent 11344551 listed to expire 14 March 2034Patent 10537572 listed to expire 1 September 2036Patent 10682351 listed to expire 1 September 2036Patent 11690854 listed to expire 19 April 2038Patent 12102637 listed to expire 20 August 2038Patent 11542239 listed to expire 23 July 2039Patent 11690845 listed to expire 27 August 2040
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 6 July 2029Patent 7419983 drug substance
  • 14 March 2034Patent 11707464
  • 14 March 2034Patent 11344551
  • 1 September 2036Patent 10537572
  • 1 September 2036Patent 10682351
  • 19 April 2038Patent 11690854
  • 20 August 2038Patent 12102637 drug product
  • 23 July 2039Patent 11542239 drug substance

1 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.